Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
34574
Description
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02454179
Lien
https://clinicaltrials.gov/show/NCT02454179
Mots-clés
Versions (2)
- 19/01/2019 19/01/2019 -
- 28/05/2021 28/05/2021 -
Détendeur de droits
see on clinicaltrials.gov
Téléchargé le
19 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Similar models
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
ID.1
Item
men and women ≥ 18 years of age
boolean
ID.2
Item
histologically or cytologically confirmed recurrent, metastatic or unresectable hnscc of the oral cavity, oropharynx, hypopharynx, and larynx that that has either progressed during or after platinum-based chemotherapy administered for metastatic disease or has recurred during or within 6 months after the completion of platinum-based neoadjuvant or adjuvant therapy
boolean
ID.3
Item
presence of radiographically measurable disease as defined by recist 1.1
boolean
ID.4
Item
ecog performance status of 0 or 1
boolean
ID.5
Item
prior malignancy (other than hnscc), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years
boolean
ID.6
Item
known central nervous system metastases and/or carcinomatous meningitis
boolean
ID.7
Item
a life-threatening illness, medical condition (including psychiatric conditions) or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
boolean
ID.8
Item
significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of starting study drug
boolean